Glucocorticoid Osteoporosis

References

• Cushing H. The basophil adenomas of the pituitary body and their clinical manifestations (pituitary ba-sophilism). Bull Johns Hopkins Hosp 1932; 1: 137–192
   Google Scholar
• Ross E J, Linch D C. Cushing's syndrome—Killing disease: Discriminatory value of signs and symptoms aiding early diagnosis. Lancet 1982; 2: 646–649
   PubMed Web of Science ®Google Scholar
• Adinoff A D, Hollister J R. Steroid-induced fractures and bone loss in patients with asthma. N Engl J Med 1983; 309: 265–268
   PubMed Web of Science ®Google Scholar
• Luengo M, Picado C, Piera C, et al. Intestinal calcium absorption and parathyroid hormone secretion in asthmatic patients on prolonged oral or inhaled steroid treatment. Eur Respir J 1991; 4: 441–444
   PubMed Web of Science ®Google Scholar
• Michel B A, Bloch D A, Fries J F. Predictors of fractures in early rheumatoid arthritis. J Rheumatol 1991; 18: 804–808
   PubMed Web of Science ®Google Scholar
• Laan R FJM, van Riel P LCM, van Erning L JThO, et al. Vertebral osteoporosis in rheumatoid arthritis patients: Effect of low dose prednisone therapy. Br J Rheumatol 1992; 31: 91–96
   PubMedGoogle Scholar
• Cooper C, Wickham C. Rheumatoid arthritis, cor-ticosteroid therapy and fracture of the proximal femur. J Bone Mineral Res 1990; 5(Suppl 2)S109
   Google Scholar
• Reid I R. Pathogenesis and treatment of steroid osteoporosis. Clin Endocrinol 1989; 30: 83–103
   PubMed Web of Science ®Google Scholar
• Lukert B, Raisz L G. Glucocorticoid-induced osteoporosis: Pathogenesis and management. Ann Intern Med 1990; 112: 352–364
   PubMed Web of Science ®Google Scholar
• Reid I R, France J T, Pybus J, Ibbertson H K. Low plasma testosterone levels in glucocorticoid-treated male asthmatics. Br Med J 1985; 291: 574
   PubMedGoogle Scholar
• Reid I R, Evans M C, Wattie D J, Ames R, Cundy T F. Bone mineral density of the proximal femur and lumbar spine in glucocorticoid-treated asthmatic patients. Osteoporosis lnt 1992; 2: 103–105
   PubMed Web of Science ®Google Scholar
• Sambrook P, Kempler S, Kelly P, Eberl S, Pocock N, Yeates M, Eisman J. Corticosteroid effects on proximal femur bone loss. J Bone Mineral Res 1990; 5: 1211–1216
   PubMed Web of Science ®Google Scholar
• Cascio L V, Bonucci E, Imbimbo B, et al. Bone loss in response to long-term glucocorticoid therapy. Bone Mineral 1990; 8: 39–51
   PubMedGoogle Scholar
• Reid I R, Heap S W. Determinants of vertebral mineral density in patients receiving chronic glucocorticoid therapy. Arch Intern Med 1990; 150: 2545–2548
   PubMedGoogle Scholar
• Reid I R, Evans M C, Stapleton J. Lateral spine den-sitometry is a more sensitive indicator of glucocorticoid-induced bone loss. J Bone Mineral Res 1992; 7: 1221–1225
   PubMed Web of Science ®Google Scholar
• Rizzato G, Tosi G, Mella C, et al. Prednisone-induced bone loss in sarcoidosis: A risk especially frequent in postmenopausal women. Sarcoidosis 1988; 5: 93–98
   PubMedGoogle Scholar
• Kugai N, Koide Y, Yamashita K, Shimauchi T, Na-Gata N, Takatani O. Impaired mineral metabolism in Cushing's syndrome: Parathyroid function, vitamin D metabolites and osteopenia. Endocrinol Jpn 1986; 3: 345–353
   Google Scholar
• Jennings B H, Andersson K-E., Johansson S A. Assessment of systemic effects of inhaled glucocorti-costeroids: comparison of the effects of inhaled budesonide and oral prednisolone on adrenal function and markers of bone turnover. Eur J Clin Pharmacol 1991; 40: 77–82
   PubMed Web of Science ®Google Scholar
• Hodsman A B, Toogood J H, Jennings B, Fraher L J, Baskerville J C. Differential effects of inhaled budesonide and oral prednisolone on serum osteocalcin. J Clin Endocrinol Metab 1991; 72: 530–540
   PubMed Web of Science ®Google Scholar
• Smith M J, Hodson M E. Effects of long term inhaled high dose beclomethasone dipropionate on adrenal function. Thorax 1983; 38: 676–681
   PubMed Web of Science ®Google Scholar
• Johansson S-A., Andersson K-E., Brattsand R, Gruv-Stad E, Hedner P. Topical and systemic glucocorticoid potencies of budesonide, beclomethasone dipropionate and prednisolone in man. Eur J Respir 1982; 63(Suppl 122)74–82
   Google Scholar
• Pedersen S, Fuglsang G. Urine cortisol excretion in children treated with high doses of inhaled corti-costeroids: A comparison of budesonide and beclomethasone. Eur Respir J 1988; 1: 433–435
   PubMed Web of Science ®Google Scholar
• Pouw E M, Prummel M F, Oosting H, Roos C M, Endert E. Beclomethasone inhalation decreases serum osteocalcin concentrations. Br Med J 1991; 302: 627–628
   PubMedGoogle Scholar
• Ali N J, Capewell S, Ward M J. Bone turnover during high dose inhaled corticosteroid treatment. Thorax 1991; 46: 160–164
   PubMed Web of Science ®Google Scholar
• Reid D M, Nicoll J J, Smith M A, et al. Corticosteroids and bone mass in asthma: Comparisons with rheumatoid arthritis and polymyalgia rheumatica. Br Med J 1986; 293: 1463–1466
   PubMedGoogle Scholar
• Packe G E, Douglas J G, McDonald A F, Robins S P, Reid D M. Bone density in asthmatic patients taking high dose inhaled beclomethasone dipropionate and intermittent systement corticosteroids. Thorax 1992; 47: 414–417
   PubMed Web of Science ®Google Scholar
• Toogood J H, Baskerville J, Jennings B, Lefcoe N M, Johansson S A. Bioequivalent doses of budesonide and prednisone in moderate and severe asthma. J Allergy Clin Immunol 1989; 84: 688–700
   PubMed Web of Science ®Google Scholar
• Lufkin E G, Wahner H W, Bergstralh E J. Reversibility of steroid-induced osteoporosis. Am J Med 1988; 85: 887–888
   PubMed Web of Science ®Google Scholar
• Manning P J, Evans M C, Reid I R. Normal bone mineral density following cure of Cushing's syndrome. Clin Endocrinol 1992; 36: 229–234
   PubMed Web of Science ®Google Scholar
• Godschalk M F, Downs R W. Effect of short-term glucocorticoids on serum osteocalcin in healthy young men. J Bone Mineral Res 1988; 3: 113–115
   PubMed Web of Science ®Google Scholar
• Bressot C, Meunier P J, Chapuy M C, et al. Histo-morphometric profile, pathophysiology and reversibility of corticosteroid-induced osteoporosis. Metab Bone Dis Rel Res 1979; 1: 303–311
   Google Scholar
• Rizzato G, Montemurro L. The reversibility of exogenous corticosteroid-induced osteoporosis. Bone Mineral 1992; 17(Suppl 1)141
   Google Scholar
• Chesney R W, Mazess R B, Rose P, Jax D K. Effect of prednisone on growth and bone mineral content in childhood glomerular disease. Am J Dis Child 1978; 132: 768–772
   PubMedGoogle Scholar
• Ruegsegger P, Medici T C, Anliker M. Corticosteroid-induced bone loss. A longitudinal study of alternate day therapy in patients with bronchial asthma using quantitative computed tomography. Eur J Clin Pharmacol 1983; 25: 615–620
   PubMed Web of Science ®Google Scholar
• Gluck O S, Murphy W A, Hahn T J, Hahn B. Bone loss in adults receiving alternate day glucocorticoid therapy. Arthritis Rheum 1981; 24: 892–898
   PubMed Web of Science ®Google Scholar
• Wilkinson R. Absorption of calcium, phosphorus and magnesium. Calcium, Phosphate and Magnesium Metabolism, B EC Nordin. Churchill Livingstone, Edinburgh 1976; 37
   Google Scholar
• Nilsen K H, Jayson M IV, Dixon A StJ. Microcrystal-line calcium hydroxyapatite compound in corticosteroid-treated rheumatoid patients: A controlled study. Br Med J 1978; 2: 1124
   PubMed Web of Science ®Google Scholar
• Reid I R, Ibbertson H K. Calcium supplements in the prevention of steroid-induced osteoporosis. Am J Clin Nutr 1986; 44: 287–290
   PubMed Web of Science ®Google Scholar
• Reid I R, King A R, Alexander C J, Ibbertson H K. Prevention of steroid-induced osteoporosis with (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD). Lancet 1988; 1: 143–146
   PubMed Web of Science ®Google Scholar
• Reid I R, Heap S W, King A R, Ibbertson H K. Two-year follow-up of bisphosphonate (APD) treatment in steroid osteoporosis. Lancet 1988; 2: 1144, (letter)
   PubMed Web of Science ®Google Scholar
• Sambrook P N, Birmingham J, Kelly S, et al. Prevention of corticosteroid osteoporosis: A comparison of calcium, calcitriol and calcitonin. J Bone Mineral Res 1992; 7(Suppl 1)S96
   Google Scholar
• Wasnich R, Benfante J, Yano K, Heilbrun L, Vogel J M. Thiazide effect on the mineral content of bone. N Engl J Med 1983; 309: 344–347
   PubMed Web of Science ®Google Scholar
• Christiansen C, Christensen M S, McNair P, et al. Prevention of early postmenopausal bone loss: Controlled 2-year study in normal females. Eur J Clin Invest 1980; 10: 273–279
   PubMed Web of Science ®Google Scholar
• Adams J S, Wahl T O, Lukert B P. Effects of hydro-chlorothiazide and dietary sodium restriction on calcium metabolism in corticosteroid treated patients. Metabolism 1981; 30: 217–221
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Ichikawa Y, Saito E, Homma M. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocortoicoid therapy. Metabolism 1983; 32: 151–156
   PubMed Web of Science ®Google Scholar
• Yamada H. Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Nippon-Naibunpi-Gakkai-Zasshi 1989; 65: 603–614
   PubMedGoogle Scholar
• Montemurro L, Fraioli P, Riboldi A, et al. Bone loss in prednisone treated sarcoidosis: A two-year follow-up. Ann Ital Med Int 1990; 5: 164–168
   PubMedGoogle Scholar
• Lukert B P, Johnson B E, Robinson R G. Estrogen and progesterone replacement therapy reduces glucocorticoid-induced bone loss. J Bone Mineral Res 1992; 7: 1063–1069
   PubMed Web of Science ®Google Scholar
• Studd J WW, Savvas M, Johnson M. Correction of corticosteroid-induced osteoporosis by percutaneous hormone implants. Lancet 1989; 1: 339
   PubMed Web of Science ®Google Scholar
• Grecu E O, Weinshelbaum A, Simmons R. Effective therapy of glucocorticoid-induced osteoporosis with medroxyprogesterone acetate. Calcif Tissue Int 1990; 46: 294–299
   PubMed Web of Science ®Google Scholar
• Cundy T, Evans M, Roberts H, et al. Reduced bone density in women using depo-medroxyprogester-one acetate for contraception. Br Med J 1991; 303: 13–16
   PubMed Web of Science ®Google Scholar
• Adami S, Fossaluzza V, Rossini M, et al. The prevention of corticosteroid-induced osteoporosis with nandrolone decanoate. Bone Mineral 1991; 15: 72–81
   Google Scholar
• Need A G. Corticosteroids and osteoporosis. Aust NZ J Med 1987; 17: 267–272
   PubMedGoogle Scholar
• Mulder H, Snelder H AA. Effect of cyclical eti-dronate regimen on prophylaxis of bone loss of glucocorticoid (prednisone) therapy in postmenopausal women. J Bone Mineral Res 1992; 7(Suppl 1)S331
   Google Scholar
• Hahn T J, Hahn B H. Osteopenia in patients with rheumatic diseases: Principles of diagnosis and therapy. Semin Arthritis Rheum 1976; 6: 165–188
   PubMedGoogle Scholar
• Dykman T R, Haralson K M, Gluck O S, et al. Effect of oral 1,25-dihydroxy-vitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases. Arthritis Rheum 1984; 27: 1336–1343
   PubMed Web of Science ®Google Scholar
• Braun J J, Birkenhager-Frenkel D H, Rietveld A H, Jr, Visser J TJ, Birkenhager J C. Influence of la(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double-blind controlled study. Clin Endocrinol 1983; 18: 265–273
   PubMedGoogle Scholar
• Bijlsma J WJ, Raymakers J A, Mosch C, et al. Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia. Clin Exp Rheumatol 1988; 6: 113–119
   PubMed Web of Science ®Google Scholar
• Di Munno O, Beghe F, Favini P, et al. Prevention of glucocorticoid-induced osteopenia: Effect of oral 25-hydroxyvitamin D and calcium. Clin Rheumatol 1989; 8: 202–207
   PubMed Web of Science ®Google Scholar
• Hahn T J, Halstead L R, Teitelbaum S L, Hahn B H. Altered mineral metabolism in glucocorticoid-induced osteopenia. J Clin Invest 1979; 64: 655–665
   PubMed Web of Science ®Google Scholar
• Morrison N A, Shine J, Fragonas J-C., et al. 1,25-dihydroxyvitamin D-responsive element and glucocorticoid repression in the osteocalcin gene. Science 1989; 246: 1158–1161
   PubMed Web of Science ®Google Scholar
• Sugimoto T, Brown A J, Ritter C, Morrissey J, Slatopolsky E, Martin K J. Combined effects of dex-amethasone and 1,25-dihydroxyvitamin D3 on parathyroid hormone secretion in cultured bovine parathyroid cells. Endocrinology 1989; 125: 638–641
   PubMed Web of Science ®Google Scholar
• Ringe J D, Welzel D. Salmon calcitonin in the therapy of corticoid-induced osteoporosis. Eur J Clin Pharmacol 1987; 33: 35–39
   PubMed Web of Science ®Google Scholar
• Rizzato G, Tosi G, Schiraldi G, et al. Bone protection with salmon calcitonin (sCT) in the long-term steroid therapy of chronic sarcoidosis. Sarcoidosis 1988; 5: 99–103
   PubMedGoogle Scholar
• Luengo M, Picado C, Del Rio L, Guanabens N, Montserrat J M, Setoain J. Treatment of steroid-induced osteopenia with calcitonin in corticosteroid-dependent asthma. Am Rev Respir Dis 1990; 142: 104–107
   PubMed Web of Science ®Google Scholar
• Montemurro L, Schiraldi G, Fraioli P, et al. Prevention of corticosteroid-induced osteoporosis with salmon calcitonin in sarcoid patients. Calcif Tissue Int 1991; 49: 71–76
   PubMed Web of Science ®Google Scholar
• Riggs B L, Hodgson S F, O'Fallon W M, et al. Effect of fluoride treatment on the fracture rate in post-menopausal women with osteoporosis. N Engl J Med 1990; 322: 802–809
   PubMed Web of Science ®Google Scholar
• Mamelle N, Meunier P J, Dusan R, et al. Risk-benefit ratio of sodium fluoride treatment in primary vertebral osteoporosis. Lancet 1988; 2: 361–363
   PubMed Web of Science ®Google Scholar
• Kleerekoper M, Peterson E L, Nelson D A, et al. A randomised trial of sodium fluoride as a treatment for postmenopausal osteoporosis. Osteoporosis Int 1991; 1: 155–161
   PubMedGoogle Scholar
• Meunier P J, Brianon D, Chavassieux P, et al. Treatment with fluoride: Bone histomorphometric findings. Osteoporosis, C Christiansen, J S Johansen, B J Riis. Osteopress, Copenhagen 1987; 824–828
   Google Scholar
• Bayley T A, Muller C, Harrison J, et al. The long-term treatment of steroid osteoporosis with fluoride. J Bone Mineral Res 1990; 5(Suppl 1)S157–S161
   Google Scholar
• Hahn T J, Halstead L R, Strates B, Imbimbo B, Baran D T. Comparison of subacute effects of oxazacort and prednisone on mineral metabolism in man. Calcif Tissue Int 1980; 31: 109–115
   PubMed Web of Science ®Google Scholar
• Caniggia A, Marchetti M, Gennari C, Vattimo A, Nicholis F B. Effects of a new glucocorticoid, oxazacort, on some variables connected with bone metabolism in man: A comparison with prednisone. Int J Clin Pharmacol 1977; 15: 126–134
   Google Scholar
• Gray R ES, Doherty S M, Galloway J, et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. Arthritis Rheum 1991; 34: 287–295
   PubMedGoogle Scholar
• Gennari C, Bernini M, Nardi P, et al. Glucocorti-coids: Radiocalcium and radiophosphate absorption in man. Osteoporosis, a Multidisciplinary Problem, A J St Dixon, R GG Russell, T CB Stamp. Royal Society of Medicine, London 1983; 75–80
   Google Scholar
• Lo Cascio V, Bonnucci E, Imbimbo B, et al. Bone loss after glucocorticoid therapy. Calcif Tissue Int 1984; 36: 435–438
   PubMed Web of Science ®Google Scholar
• Gennari C, Imbimbo B. Effects of prednisone and deflazacort on vertebral bone mass. Calcif Tissue Int 1985; 37: 592–593
   PubMed Web of Science ®Google Scholar
• Loftus J, Allen R, Hesp J, et al. Randomized, double-blind trial of deflazacort versus prednisone in juvenile chronic (or rheumatoid) arthritis: A relatively bone-sparing effect of deflazacort. Paediatrics 1991; 88: 428–436
   PubMed Web of Science ®Google Scholar
• Olgaard K, Storm T, Wowern N V, et al. Glucocorticoid induced osteoporosis in the lumbar spine, forearm and mandible of nephrotic patients. A double-blind study on the high-dose long-term effects of prednisone versus deflazacort. Calcif Tissue Int 1992; 50: 490–497
   PubMed Web of Science ®Google Scholar
• Balsan S, Steru D, Bourdeau A, Grimberg R, Lenoir G. Effects of long-term maintenance therapy with a new glucocorticoid, deflazacort, on mineral metabolism and statural growth. Calcif Tissue Int 1987; 40: 303–309
   PubMed Web of Science ®Google Scholar
• Aicardi G, Milani S, Imbimbo B, et al. Comparison of growth retarding effects induced by two different glucocorticoids in prepubertal sick children: An interim long-term analysis. Calcif Tissue Int 1991; 48: 283–287
   PubMed Web of Science ®Google Scholar
• Medici T C, Ruegsegger P. Does alternate-day clo-prednol therapy prevent bone loss? A longitudinal double-blind, controlled clinical study. Clin Pharmacol Ther 1990; 48: 455–466
   PubMed Web of Science ®Google Scholar